Contingency management is the evidence-based standard for stimulant use disorder, but reimbursement gaps and anti-kickback law keep the treatment rare in practice.
Key Takeaways
- The evidence is not in question: Decades of trials show contingency management, which rewards patients for verified abstinence, is the most effective treatment for stimulant use disorder. There is no approved medication that comes close.
- Funding runs through narrow channels: Because most plans do not cover it, programs lean on SAMHSA grants or state Medicaid 1115 waivers to pay for incentives. Neither is a stable foundation for a permanent service line.
- Federal fraud law is the real constraint: Paying patients can trigger the Anti-Kickback Statute, the Beneficiary Inducements law, and EKRA, so incentive caps and strict protocols are not optional. Getting the guardrails wrong turns a treatment into a felony exposure.
- The window is opening slowly: Regulators raised the federal grant incentive limit tenfold and more states are testing coverage, giving operators a path that the math would not support a few years ago. Building a compliant program now is a bet that reimbursement will follow the evidence.
The intervention that decades of research call the single most effective treatment for methamphetamine and cocaine addiction can look, from across a clinic waiting room, almost too simple to be medicine. A patient provides a urine sample. If it is negative for stimulants, they draw a slip from a fishbowl or watch a small credit load onto a gift card: five dollars, then eight, then a little more for the next clean test, the reward climbing with each success. That is the whole mechanism.
It has a clinical name, contingency management, touting a behavioral logic that runs straight back to the operant-conditioning experiments of the mid-twentieth century. It works when a great deal of more sophisticated-sounding treatment does not.
It also happens to be one of the hardest things in American health care to pay for, and one of the easiest ways for a well-meaning provider to walk into a federal fraud investigation. That contradiction, an effective treatment that the payment and legal systems are built to resist, is the story of contingency management in 2026, and it is becoming urgent because the drugs it treats are killing more people than ever.
The Fourth Wave of the Overdose Crisis Has No Approved Medication
For most of the past decade, the overdose story in America was a story about opioids, and the response was built around medication: buprenorphine, methadone, or naloxone to reverse an overdose in progress. Stimulants broke that framework.
Methamphetamine and cocaine, increasingly laced into the same fentanyl supply that drove the opioid deaths, now turn up in a majority of overdose fatalities, a shift epidemiologists have taken to calling the fourth wave. And here the medical toolkit runs out. There is no naloxone for a stimulant overdose, because there is no receptor to block. There is no approved medication for stimulant use disorder at all, nothing equivalent to the drugs that made opioid addiction, for the first time, a condition a primary-care doctor could manage now that the buprenorphine prescriber pool has widened.
What exists instead is contingency management. In head-to-head terms, it seems effective. Across dozens of trials, rewarding patients for drug-negative tests produces higher abstinence rates than counseling, cognitive behavioral therapy, or any pharmacology tried against stimulants, and some of that benefit persists after the rewards stop. Clinical guidelines now name it the first-line treatment. The catch is that the reward is the treatment. Take away the incentive and you have taken away the medicine, which means the question of who pays for the gift cards is not administrative trivia. It is the difference between offering the therapy and not.
Why Contingency Management Reimbursement Is So Hard to Find
Most private insurers do not cover contingency management, and most state Medicaid programs historically have not either, which leaves providers assembling funding from a patchwork of grants and waivers. The largest single source has been SAMHSA’s State Opioid Response grants, which can underwrite incentives even though the program’s name points at opioids, on the logic that stimulant use rarely travels alone. The more durable route is a Medicaid section 1115 demonstration waiver: California opened the door in 2021 with its Recovering Incentives pilot inside CalAIM, and Washington, Montana, and a growing list of states have followed, testing whether a public payer can cover the treatment without inviting abuse.
None of this adds up to a business a provider can bank on. Grants expire and get recompeted. Waivers are time-limited demonstrations that a new administration can decline to renew, and California’s runs only through the end of 2026, even as the state absorbs the largest Medicaid restructuring in the program’s history. For an operator weighing whether to stand up a stimulant program, the reimbursement picture looks nothing like the relatively settled economics of medication-assisted treatment for opioids, where uneven payment is a real constraint but a payable service still exists. Contingency management asks a provider to build a service line on soft money, which is why so few have, and why a treatment with unusually strong evidence remains unusually rare on the ground.
The Anti-Kickback Tripwire Under the Gift Card
The deeper obstacle is not budgetary but criminal. Handing money to a patient who is also a Medicaid or Medicare beneficiary runs directly at a wall of federal fraud law: the Anti-Kickback Statute, which bars paying anyone to induce federally reimbursable care; the Beneficiary Inducements provision, which specifically targets rewards likely to steer a patient’s choice of provider; and EKRA, the Eliminating Kickbacks in Recovery Act, passed in 2018 to stop patient-brokering in exactly the addiction-treatment world where contingency management lives. A gift card for a clean urine screen can, read uncharitably, look like every one of those things.
The government has left a narrow, navigable path, though a more complicated one than it first appears. Two separate limits are often confused. The one most providers cite is SAMHSA’s, which for years capped incentives paid through its grants at seventy-five dollars per patient a year, a figure researchers said was far too low to work; in January 2025 SAMHSA raised it roughly tenfold, to seven hundred and fifty dollars a year, and confirmed that vouchers and gift cards, though not cash, are allowed. The other limit lives in fraud law: the HHS Office of Inspector General created a patient-engagement safe harbor, with an inflation-adjusted ceiling around six hundred dollars a year, but pointedly declined to extend it to cash or cash-equivalent rewards like gift cards, the very form contingency management relies on. The OIG has also stressed that falling outside a safe harbor does not make an incentive automatically illegal. Programs that follow a documented, evidence-based protocol and disburse rewards as vouchers or gift cards rather than cash are on defensible ground, and a program that cannot fit neatly inside a safe harbor can seek an OIG advisory opinion, as at least one digital contingency-management company has done, rather than guess. The same heightened program-integrity scrutiny now falling on the rest of behavioral health means a sloppily run incentive program is a liability, not just a compliance headache.
A Narrow Opening for Addiction Treatment Operators
What has changed, and what makes this worth an operator’s attention now rather than later, is that the two obstacles are eroding at once. The federal grant ceiling has been raised tenfold, removing the fear that any meaningful incentive was too small to matter. The coverage map is filling in, waiver by waiver, as states run demonstrations that give the treatment a real, if provisional, payer. Neither shift is finished, and a program built today still depends on grant cycles and time-limited waivers that could lapse. But the field has moved from a place where contingency management was effectively unfundable to one where a careful provider can now assemble a compliant, paid program where a few years ago the math simply did not work, particularly for the dual-diagnosis and polysubstance patients who already dominate treatment caseloads and whom the billing system tends to split into separate, poorly reimbursed pieces.
The strategic read is that this is a bet on alignment. The evidence for contingency management has been settled for years; what has lagged is the willingness of payers and the comfort of regulators, and both are inching toward the science. An operator who builds the protocol discipline now, documents fidelity, and keeps incentives inside the safe harbor is positioned for the moment when coverage becomes routine rather than experimental. That moment is not here. For a treatment that works this well against a drug supply this lethal, the more uncomfortable question is why getting paid to use it still counts as the hard part.
